

Quarterly Report as of 31 December 2020

Financial year 2020 successfully completed

- Guidance for group revenues and adjusted EBITDA achieved
- Adjusted earnings per share and Free Cash flow better than expected

Key financial figures Q4/2020

- 18 % increase in revenues and 5 % organically
- 20 % increase in recurring revenues
- 5 % increase in adjusted EBITDA to 60 MEUR
- Continued increase in Free Cash flow
- Strong adjusted earnings per share to 0.46 EUR (previous year's quarter: 0.37 EUR)

FINANCIAL KEY FIGURES

EUR '000	01.10.- 31.12.2020	01.10.- 31.12.2019*	Change	01.01.- 31.12.2020	01.01.- 31.12.2019*	Change
Revenues	242,910	206,084	+18%	837,259	745,808	+12%
Organic growth in %	4.9%	0.4%		4.2%	-0.4%	
Recurring Revenues in %	59%	58%		63%	62%	
Adjusted EBITDA	59,637	56,614	+5%	214,882	198,132	+8%
Adjusted Margin	25%	27%		26%	27%	
Adjusted EPS (EUR) - diluted	0.46	0.37	+24%	1.88	1.74	+9%
CAPEX	16,641	2,978	+459%	55,069	43,339	+27%
Adjusted Free Cash flow	16,483	9,419	+75%	100,744	93,288	+8%
Number of shares outstanding ('000)	53,735	48,413		53,735	48,413	

* Adjusted key figures for 2019 presented on a pro forma basis: excluding the one-time effect of stock option-based compensation expenses against cash settlement for a former Executive Board member and non-recurring expenses for discontinued M&A transactions.

NOTES

The figures and information contained in this financial report are preliminary and unaudited and are subject to audit and approval by the Supervisory Board. The publication of the final audited results for the fourth quarter of 2020 and the Annual Report 2020 will take place on 25 March 2021.

Unless otherwise stated, all figures and explanations in this report refer to the fourth quarter of 2020 and 2019, i.e. the three-month period 1 October - 31 December (Q4), and all percentage changes refer to the respective year-on-year comparison. Due to rounding, totals and percentages presented in this report may not add up precisely to the totals provided.

BUSINESS DEVELOPMENT - SIGNIFICANT EVENTS

COVID-19 pandemic impact

CompuGroup Medical reacted early and comprehensively to the COVID-19 pandemic by implementing appropriate protective measures for employees and by delivering innovative offerings to customers. To this end, increased development and personnel efforts were undertaken to provide the best possible support to our customers in all segments.

We continue to expect a significantly increased growth opportunity in the medium term due to the pandemic based increased willingness to adopt digital networking solutions in the healthcare business.

Acquisition of eMDs in the United States

CompuGroup Holding USA, Inc. a wholly owned subsidiary of CompuGroup Medical SE & Co. KGaA, entered into an agreement in December with MDeverywhere Midco, Inc, USA, the sole indirect shareholder of eMDs, Inc, USA (collectively "eMDs"), to acquire 100 % of the shares of eMDs. As part of the closing, all shares in the company will be consolidated for the first time as of 31 December 2020. The main products of eMDs are physician information systems and outsourcing services for the billing of medical services.

The consideration transferred for the acquisition amounts to approximately USD 230 million (MEUR 189). The financing was provided from cash, current Cash flow and a drawdown of the revolving multi-year credit facility in the low double-digit million Euro range. For the financial year 2019 / 2020 (ended 31 March 2020), eMDs generated revenues of approximately MEUR 79 with an adjusted EBITDA of approximately MEUR 16 with more than 60,000 service providers. eMDs currently employs approximately 1,400 associates.

Acquisition of Schuyler House in the United States

In December, CompuGroup Holding USA, Inc. a wholly owned subsidiary of CompuGroup Medical SE & Co. KGaA, acquired 100 % of the shares in Schuyler House Inc. based in Valencia, USA. Schuyler House focuses on the Physician Office Lab (POL), small to mid-sized hospitals, clinics and independent reference labs. They have installations in the United States, Central America, Ghana, and Malaysia. Schuyler House's initial consolidation date is 31 December 2020.

Focus on Hospital Future Act and IT security

The adoption of the Hospital Future Act (KHZG) in September 2020 creates additional opportunities for further growth in the German home market of the Hospital Information Systems segment. The aim of this program of about EUR 4 billion is to sustainably accelerate digitalization in the healthcare sector, which is the core competency of CompuGroup Medical. Essential pillars are the creation of a digital infrastructure and the strengthening of IT security. Positive effects are expected to continue in 2021 and beyond.

Further expansion of digital networking solutions

In the aftermath of the quarterly financial statements Q3/2020, a planned cooperation with NOWEDA, operator of the online portal IhreApotheken.de, was announced. The goal is the joint further digitalization of the patient journey. By combination of IhreApotheken.de and CLICKDOC, it will be possible in the future to order drugs in local pharmacies where it is legally allowed. The planned cooperation will enable the ordering of medicines and the redemption of prescriptions via CLICKDOC in the chosen pharmacy.

EARNINGS DEVELOPMENT IN THE GROUP

EUR '000	01.10.- 31.12.2020	01.10.- 31.12.2019	01.01.- 31.12.2020	01.01.- 31.12.2019
Revenues	242,910	206,084	837,259	745,808
Capitalized inhouse services and other income	10,140	12,696	42,434	38,028
Expenses for goods and services purchased	-53,984	-42,751	-156,178	-138,956
Personnel expenses	-100,727	-89,043	-377,052	-339,442
Other expenses and net impairment losses on financial and contract assets	-50,152	-34,978	-148,987	-127,312
EBITDA	48,188	52,008	197,476	178,126
Depreciation of property, plant and equipment, right-of-use assets and amortization of intangible assets	-23,183	-18,613	-75,427	-62,855
EBIT	25,004	33,395	122,049	115,270
Financial result	-5,664	-2,421	-11,343	-7,525
EBT	19,340	30,973	110,705	107,745
Income taxes for the period	-10,109	-17,578	-37,518	-41,594
CONSOLIDATED NET INCOME FOR THE PERIOD	9,231	13,396	73,188	66,151

Revenues in the fourth quarter increased by MEUR 36.8 (18 %) to MEUR 242.9 compared to the prior-year quarter, of which MEUR 25.4 resulted from inorganic revenues (prior year: MEUR - 2.7). Organic growth in the fourth quarter 2020 amounts to 4.9 % year-over-year, which is mainly due to one-off revenues from the software upgrade in the context of the Telematics Infrastructure. Excluding the revenues of the Telematics Infrastructure, organic growth amounts to - 4.1 % in the quarter.

Revenues in the financial year 2020 exceeded those of the prior year by MEUR 91.5 (12 %) and amounted to MEUR 837.3. Inorganic revenues accounted for MEUR 65.0 (prior year: MEUR 1.1), resulting in organic growth of 4.2 % (prior year: - 0.4 %) and adjusted for Telematics Infrastructure 2.0 % (prior year: 6.7 %).

Adjusted consolidated earnings before interest, taxes, depreciation and amortization (adjusted Group EBITDA) for the fourth quarter of 2020 amounted to MEUR 59.6 (prior year: MEUR 56.6 on a pro forma basis) with an adjusted EBITDA margin of 25 % (prior year: 27 %).

For the financial year 2020, adjusted Group EBITDA amounts to MEUR 214.9 (prior year: MEUR 198.1 on a pro forma basis) with an adjusted EBITDA margin of 26 % (prior year: 27 %).

Adjusted Group EBITDA is derived from reported EBITDA as shown below:

EUR '000	01.10.- 31.12.2020	01.10.- 31.12.2019*	01.01.- 31.12.2020	01.01.- 31.12.2019*
EBITDA REPORTED	48,188	52,008	197,476	178,126
Adjustments:				
M&A Transactions	7,081	4,606	10,853	16,108
Share-based option programs	4,369	0	5,882	3,898
Restructuring program expenses	0	0	0	0
Other non-operative, extraordinary or one-time effects	0	0	672	0
EBITDA ADJUSTED	59,637	56,614	214,882	198,132

* Adjusted key figures for 2019 presented on a pro forma basis: Effects taken into account are the one-time effect of stock option-based compensation expenses against cash settlement for a former Management Board member and further the non-recurring expenses for discontinued M&A transactions.

Based on a preliminary tax calculation, the Group's net income for the fourth quarter amounts to MEUR 9.2 compared to MEUR 13.4 in the prior year's period.

The preliminary consolidated net income for the financial year 2020 amounts to MEUR 73.2 and is thus MEUR 7.0 higher than in the prior year.

Preliminary adjusted earnings per share are as follows:

EUR '000	01.10.- 31.12.2020	01.10.- 31.12.2019*	01.01.- 31.12.2020	01.01.- 31.12.2019*
CONSOLIDATED NET INCOME OF THE PERIOD (ALLOCATED TO SHAREHOLDERS OF THE PARENT COMPANY)	9,171	13,387	72,961	65,819
Adjustments:				
M&A Transactions	12,424	4,606	19,415	16,108
Share-based option programs	3,676	0	4,735	3,898
Restructuring program expenses	0	0	0	0
Other non-operative, extraordinary or one-time effects	0	0	1,271	0
ADJUSTED CONSOLIDATED NET INCOME FOR THE PERIOD (ALLOCATED TO SHAREHOLDERS OF THE PARENT COMPANY)	25,272	17,993	98,382	85,825
ADJUSTED UNDILUTED EARNINGS PER SHARE (IN EUR)	0.47	0.37	1.92	1.76
ADJUSTED DILUTED EARNINGS PER SHARE (IN EUR)	0.46	0.37	1.88	1.74
weighted average of outstanding shares acc. to IAS 33 - undiluted ('000)**	53,841	48,191	51,212	48,776
weighted average of outstanding shares acc. to IAS 33 - diluted ('000)**	54,838	48,462	52,212	49,422

* Adjusted key figures for 2019 presented on a pro forma basis: Effects taken into account are the one-time effect of stock option-based compensation expenses against cash settlement for a former Management Board member and further the non-recurring expenses for discontinued M&A transactions.

** Weighted average number of outstanding shares for the quarter calculated from the earnings per shares for the quarter

In the fourth quarter of 2020, Cash flow from operating activities amounted to MEUR 32.0 compared to MEUR 10.3 in the prior year's period.

At MEUR 149.9, Cash flow from operating activities in the 2020 financial year is MEUR 39.4 higher than in the prior year. The derivation of Free Cash flow and adjusted Free Cash flow is presented below:

EUR '000	01.10.- 31.12.2020	01.10.- 31.12.2019*	01.01.- 31.12.2020	01.01.- 31.12.2019*
OPERATING CASH FLOW	32,007	10,290	149,931	110,495
CASH FLOW FROM INVESTING ACTIVITIES	-206,644	-72,973	-457,116	-139,444
./. Net cash outflow for company acquisitions (less acquired cash and cash equivalents and prepayments in previous periods)	188,819	69,443	397,108	94,857
./. Cash outflow for acquisitions from prior periods	1,404	559	3,132	1,753
./. Cash inflow from the disposal of subsidiaries and business units	-220	-7	-220	-505
./. Cash outflow for capital expenditures in joint ventures and other equity investments	0	0	2,027	0
+/- Extraordinary effects	0	0	0	0
FREE CASH FLOW	15,366	7,311	94,862	67,156
Operating Cash flow adjustments	1,117	2,108	5,882	26,132
ADJUSTED FREE CASH FLOW	16,483	9,419	100,744	93,288

* Adjusted key figures for 2019 presented on a pro forma basis: excluding the one-time effect of stock option-based compensation expenses against cash settlement for a former Management Board member and non-recurring expenses for discontinued M&A transactions.

Net debt as of 31 December 2020 is MEUR 480, MEUR 13 higher than the net debt of the prior year. The leverage is 2.0 (31 December 2019: 2.4) and thus meets the requirements under the existing credit agreements.

EARNINGS DEVELOPMENT OF THE BUSINESS SEGMENTS

Ambulatory Information Systems (AIS)

MEUR	01.10 - 31.12.2020	01.10 - 31.12.2019	Change	01.01 - 31.12.2020	01.01 - 31.12.2019	Change
Revenues to third parties	122.4	113.9	8%	466.7	444.6	5%
thereof organic revenues*	121.0	116.3	4%	451.2	443.8	2%
thereof recurring revenues	70%	69%		71%	69%	
EBITDA adjusted**	40.2	43.3	-7%	171.7	161.1	7%
in % of revenues	33%	38%		37%	36%	

* Adjusted for revenues of companies consolidated for the first time in the reporting period or of companies consolidated for the last time in the prior-year period.

** Adjusted key figures for 2019 presented on a pro forma basis: excluding the one-time effect of stock option-based compensation expenses against cash settlement for a former Management Board member and non-recurring expenses for discontinued M&A transactions.

- The software business with physicians and dentists generates revenues of MEUR 122.4 for the fourth quarter of 2020, an increase of 8 % year-on-year. The increased revenue for the fourth quarter 2020 is mainly due to the acquisition of Epsilog and higher Telematics Infrastructure revenues.
- Inorganic effects contributed MEUR 1.4 to revenues for the fourth quarter of 2020.
- Organic revenue development is 4 % above the prior year. Excluding the Telematics Infrastructure, organic revenue development is negative at - 3 %. The decline in revenue is due to the negative impact of the COVID-19 pandemic on the dental and US businesses in particular. In addition, the fourth quarter of 2019 was positively impacted by the Windows 10 launch and the rollout of the electronic health record in Austria.
- Recurring revenues in the AIS segment increased by 10 % to MEUR 86.0.
- Adjusted EBITDA of MEUR 40.2 was - 7 % lower than in the fourth quarter of last year, due to a higher proportion of hardware sales and increased marketing, sales and software maintenance activities.

Pharmacy Information Systems (PCS)

MEUR	01.10 - 31.12.2020	01.10 - 31.12.2019	Change	01.01 - 31.12.2020	01.01 - 31.12.2019	Change
Revenues to third parties	41.3	36.0	15%	135.4	119.4	13%
thereof organic revenues*	41.8	36.3	15%	135.0	119.4	13%
thereof recurring revenues	47%	53%		56%	60%	
EBITDA adjusted**	12.1	10.9	11%	37.6	31.9	18%
in % of revenues	29%	30%		28%	27%	

* Adjusted for revenues of companies consolidated for the first time in the reporting period or of companies consolidated for the last time in the prior-year period.

** Adjusted key figures for 2019 presented on a pro forma basis: excluding the one-time effect of stock option-based compensation expenses against cash settlement for a former Management Board member and non-recurring expenses for discontinued M&A transactions.

- The Pharmacy Software business generates revenues of MEUR 41.3 for the fourth quarter of 2020, representing organic growth of 15 % year-on-year.
- This growth is attributable to the rollout of the Telematics Infrastructure in the pharmacy business, which started in July. Excluding the Telematics Infrastructure, revenue was 13 % below the strong prior-year figure. This was due to an exceptionally good quarter in Italy (government-backed IT investments at the end of the year) and the rollout of Windows 10. In addition, the Italian pharmacy business was negatively impacted by COVID-19 for the fourth quarter. Moreover, priority was deliberately given to the expansion of the Telematics Infrastructure in the pharmacy business in Germany for the fourth quarter of 2020, which is the key factor behind the excellent revenue growth of 15 %.
- Recurring revenues in the PCS segment increased by 3 % compared to the prior year's period to MEUR 19.6.
- Adjusted EBITDA of EUR 12.1 million is 11 % above prior year's figure of EUR 10.9 million, mainly due to the rollout of the Telematics Infrastructure in the pharmacy business.

Hospital Information Systems (HIS)

MEUR	01.10 - 31.12.2020	01.10 - 31.12.2019	Change	01.01 - 31.12.2020	01.01 - 31.12.2019	Change
Revenues to third parties	63.4	41.4	53%	186.6	135.9	37%
thereof organic revenues*	40.0	41.4	-3%	140.0	135.9	3%
thereof recurring revenues	56%	50%		61%	58%	
EBITDA adjusted**	14.5	8.8	64%	31.9	19.3	65%
in % of revenues	23%	21%		17%	14%	

* Adjusted for revenues of companies consolidated for the first time in the reporting period or of companies consolidated for the last time in the prior-year period.

** Adjusted key figures for 2019 presented on a pro forma basis: excluding the one-time effect of stock option-based compensation expenses against cash settlement for a former Management Board member and non-recurring expenses for discontinued M&A transactions.

- The strong revenue growth in the HIS segment amounts to 53 % and is attributable to the acquisition of the IT Healthcare portfolio from Cerner Corporation.
- Organic revenues were down 3 % on the prior year. This is mainly attributable to a strong prior-year quarter due to hardware revenues in connection with the "NÖKIS" rollout in Lower Austria. Notwithstanding this, a good operating performance was recorded for the fourth quarter in the hospital business.
- Recurring revenues increased by 73 % to MEUR 35.8 due to acquisitions.
- Adjusted EBITDA of MEUR 14.5 was significantly above prior year's figure of MEUR 8.8 and the EBITDA margin increased to 23 %. This strong increase is mainly due to the acquisition of the IT Healthcare portfolio from Cerner and an improved revenue mix (hardware revenue in the prior year).

Consumer and Health Management Information Systems (CHS)

MEUR	01.10 - 31.12.2020	01.10 - 31.12.2019	Change	01.01 - 31.12.2020	01.01 - 31.12.2019	Change
Revenues to third parties	15.1	14.7	3%	48.1	45.7	5%
thereof organic revenues*	15.5	14.7	5%	49.0	45.4	8%
thereof recurring revenues	12%	11%		12%	8%	
EBITDA adjusted**	2.9	3.4	-15%	8.3	11.2	-26%
in % of revenues	19%	23%		17%	25%	

* Adjusted for revenues of companies consolidated for the first time in the reporting period or of companies consolidated for the last time in the prior-year period.

** Adjusted key figures for 2019 presented on a pro forma basis: excluding the one-time effect of stock option-based compensation expenses against cash settlement for a former Management Board member and non-recurring expenses for discontinued M&A transactions.

- CHS segment revenues increased by 3 % to MEUR 15.1.
- Adjusted for inorganic effects, organic revenues growth amounted to 5 %, resulting from a positive development in the Intermedix business.
- Adjusted EBITDA decreased to MEUR 2.9, mainly due to increased development expenses for platform.

Other segments and consolidation

MEUR	01.10 - 31.12.2020	01.10 - 31.12.2019	Change	01.01 - 31.12.2020	01.01 - 31.12.2019	Change
Revenues to third parties	0.6	-0.0	2,146%	0.5	0.2	215%
EBITDA adjusted*	-10.0	-9.8	-3%	-34.5	-25.3	-36%

* Adjusted key figures for 2019 presented on a pro forma basis: excluding the one-time effect of stock option-based compensation expenses against cash settlement for a former Management Board member and non-recurring expenses for discontinued M&A transactions.

- Adjusted EBITDA in other segments and consolidation is MEUR - 0.2 below prior year.
- Adjusted one-time effects in this segment for the fourth quarter of 2020 mainly comprise expenses in connection with stock option programs of MEUR 4.4 and M&A costs of MEUR 4.1. The fourth quarter of 2019 on a pro forma basis was adjusted for M&A costs of MEUR 4.6.

GUIDANCE

Group

For 2021, CGM expects revenues in a range of MEUR 1,000 to MEUR 1,040, corresponding to revenue growth of 19 % to 24 %. This includes significant consolidation effects mainly from the two major acquisitions completed in financial year 2020. Organic growth is expected in a range between 4 % and 8 %.

- Adjusted EBITDA is expected in a range of MEUR 210 to MEUR 230.
- Adjusted earnings per share are expected to be between EUR 1.70 and EUR 1.95.
- Capex is expected to be in the range of MEUR 70 to MEUR 80.
- Free Cash flow is expected to be above MEUR 80.

Segments

With effect from the beginning of 2021, the segmentation has again been adjusted to further improve transparency. Thus, the revenue and earnings contributions resulting from the Telematics Infrastructure will be reclassified from the AIS and PCS segments to the CHS segment. For the reporting segments in the new structure announced in the fourth quarter of 2020 and effective from 1 January 2021, the following development is expected for the financial year 2021:

- AIS revenues including acquisitions completed as of 31 December 2020 are expected to be in the range of MEUR 485 to MEUR 500.
- The PCS segment is expected to generate revenues of MEUR 115 to MEUR 120.
- Revenues for the HIS segment are expected to be in the range of MEUR 240 to MEUR 250.
- The new CHS segment is expected to generate revenues between MEUR 160 and MEUR 170 in 2020.

The above guidance for the current financial year was prepared in January 2021 and does not take into account any effects from currently pending acquisitions and potential transactions in the course of the financial year 2021. The guidance for 2021 represents management's best estimate of future market conditions and the development of CompuGroup Medical's business segments in this environment and may be affected in particular by delays in the implementation of the Telematics Infrastructure for which the Company is not responsible. In addition, the further impact of the global COVID-19 pandemic cannot be fully assessed. The 2021 guidance could also be influenced by exchange rate effects (in particular changes in the U.S. dollar exchange rate against the Euro).

CompuGroup reports adjusted key figures for the operating result (EBITDA) and earnings per share since the financial year 2020. These key figures are not defined under International Financial Reporting Standards (IFRS) and should be regarded as supplementary information. Adjusted EBITDA and adjusted earnings per share exclude effects from the acquisition and disposal of subsidiaries, business units and investments (including effects from the subsequent measurement of contingent purchase price liabilities), impairment losses and write-ups on investments, effects from the acquisition, construction and disposal of real estate, impairment losses and write-ups on owner-occupied property, as well as expenses in connection with share-based payment programs for executives, taxes attributable to the above effects, and other non-operating or non-periodic non-recurring effects.

Interim Statement of Financial Position

as of 31 December 2020

ASSETS

EUR '000	31.12.2020	31.12.2019
Non-current assets		
Intangible assets	1,083,091	668,329
Property, plant and equipment	91,809	88,064
Right-of-use assets	44,552	43,189
Investments in associates and joint ventures (valued at-equity)	2,001	938
Other investments	640	1,458
Finance lease receivables	15,267	14,826
Contract assets	36	0
Other financial assets	10,266	9,003
Other non-financial assets	1,200	1,200
Deferred taxes	4,959	5,923
	1,253,822	832,930
Current assets		
Inventories	18,158	27,492
Trade receivables	136,406	102,982
Finance lease receivables	8,588	7,784
Contract assets	25,650	9,092
Other financial assets	2,663	3,137
Other non-financial assets	24,406	16,918
Income tax receivables	16,652	19,177
Cash & cash equivalents	75,910	46,350
	308,433	232,932
	1,562,256	1,065,862

SHAREHOLDER EQUITY AND LIABILITIES

EUR `000	31.12.2020	31.12.2019
Equity		
Subscribed capital	53,735	53,219
Treasury shares	0	-86,322
Reserves	584,670	292,208
Capital and reserves allocated to the shareholders of the parent company	638,405	259,105
Non-controlling interests	232	811
	638,636	259,916
Non-current liabilities		
Provisions for post-employment benefits and other non-current provisions	45,080	30,979
Liabilities to banks	461,061	410,838
Contract liabilities	6,628	6,114
Purchase price liabilities	4,191	7,791
Lease liabilities	28,000	28,489
Other financial liabilities	9,144	13,619
Other non-financial liabilities	1,201	1,193
Deferred taxes	74,696	70,619
	630,000	569,642
Current liabilities		
Liabilities to banks	35,298	38,810
Contract liabilities	68,508	42,485
Purchase price liabilities	11,666	10,119
Trade payables	63,728	47,093
Income tax liabilities	17,346	17,973
Other provisions	48,679	42,156
Lease liabilities	16,872	14,636
Other financial liabilities	9,837	7,849
Other non-financial liabilities	21,687	15,183
	293,620	236,304
	1,562,256	1,065,862

Interim Income Statement

for the reporting period of 1 January – 31 December 2020

EUR '000	01.10.- 31.12.2020	01.10.- 31.12.2019	01.01.- 31.12.2020	01.01.- 31.12.2019
Revenues	242,910	206,084	837,259	745,808
Capitalized inhouse services	6,901	7,626	31,872	24,570
Other income	3,239	5,070	10,562	13,458
Expenses for goods and services purchased	-53,984	-42,751	-156,178	-138,956
Personnel expenses	-100,727	-89,043	-377,052	-339,442
Net impairment losses on financial and contract assets	-1,937	-1,628	-4,292	-4,037
Other expenses	-48,215	-33,351	-144,695	-123,275
Earnings before interest, taxes, depreciation and amortization (EBITDA)	48,188	52,008	197,476	178,126
Depreciation of property, plant and equipment and right-of-use assets	-8,721	-7,706	-30,856	-28,521
Earnings before interest, taxes and amortization (EBITA)	39,466	44,302	166,620	149,605
Amortization of intangible assets	-14,462	-10,907	-44,571	-34,335
Earnings before interest and taxes (EBIT)	25,004	33,395	122,049	115,270
Result from companies accounted for using the equity method	-146	508	-931	-1,785
Financial income	-97	381	2,651	2,067
Financial expenses	-5,421	-3,311	-13,063	-7,808
Earnings before taxes (EBT)	19,340	30,973	110,705	107,745
Income taxes for the period	-10,109	-17,578	-37,518	-41,594
Results from continued operations	9,231	13,396	73,188	66,151
Profit for the period from discontinued operations	0	0	0	0
Consolidated net income for the period	9,231	13,396	73,188	66,151
of which: allocated to shareholders of the parent company	9,171	13,387	72,961	65,819
of which: allocated to non-controlling interests	60	9	227	332
Earnings per share (from continuing operations)				
undiluted (EUR)	0.16	0.28	1.42	1.35
diluted (EUR)	0.16	0.27	1.40	1.33

Appendix

as of 31 December 2020

EARNINGS DEVELOPMENT ACCORDING TO THE NEW SEGMENT STRUCTURE EFFECTIVE FROM 1 JANUARY 2021

The segmentation will be adjusted for the financial year 2021. Essentially, the revenues and earnings of the Telematics Infrastructure from the segments AIS and PCS will be included in the CHS segment.

For comparison, the following tables show the segment earnings development for 2020 (including the prior year) in the new structure, active from 1 January 2021.

Ambulatory Information Systems (AIS)

MEUR	01.10 - 31.12.2020	01.10 - 31.12.2019	Change	01.01 - 31.12.2020	01.01 - 31.12.2019	Change
Revenues to third parties	96.7	95.2	2%	375.2	352.0	7%
thereof recurring revenues	74%	70%		75%	74%	
EBITDA adjusted*	29.8	30.9	-4%	117.8	117.4	0%
in % of revenues	31%	32%		31%	33%	

* Adjusted key figures for 2019 presented on a pro forma basis: excluding the one-time effect of stock option-based compensation expenses against cash settlement for a former Management Board member and non-recurring expenses for discontinued M&A transactions.

Pharmacy Information Systems (PCS)

MEUR	01.10 - 31.12.2020	01.10 - 31.12.2019	Change	01.01 - 31.12.2020	01.01 - 31.12.2019	Change
Revenues to third parties	30.4	35.4	-14%	116.8	116.7	0%
thereof recurring revenues	62%	54%		65%	62%	
EBITDA adjusted*	9.5	10.6	-10%	33.5	30.4	10%
in % of revenues	31%	30%		29%	26%	

* Adjusted key figures for 2019 presented on a pro forma basis: excluding the one-time effect of stock option-based compensation expenses against cash settlement for a former Management Board member and non-recurring expenses for discontinued M&A transactions.

Hospital Information Systems (HIS)

MEUR	01.10 - 31.12.2020	01.10 - 31.12.2019	Change	01.01 - 31.12.2020	01.01 - 31.12.2019	Change
Revenues to third parties	63.4	41.4	53%	186.6	135.9	37%
thereof recurring revenues	56%	50%		61%	58%	
EBITDA adjusted*	14.4	8.8	64%	31.9	19.3	65%
in % of revenues	23%	21%		17%	14%	

* Adjusted key figures for 2019 presented on a pro forma basis: excluding the one-time effect of stock option-based compensation expenses against cash settlement for a former Management Board member and non-recurring expenses for discontinued M&A transactions.

Consumer and Health Management Information Systems (CHS)

MEUR	01.10 - 31.12.2020	01.10 - 31.12.2019	Change	01.01 - 31.12.2020	01.01 - 31.12.2019	Change
Revenues to third parties	52.3	33.2	58%	158.4	139.1	14%
thereof recurring revenues	32%	41%		34%	35%	
EBITDA adjusted*	11.2	10.1	11%	48.3	37.6	29%
in % of revenues	21%	30%		31%	27%	

* Adjusted key figures for 2019 presented on a pro forma basis: excluding the one-time effect of stock option-based compensation expenses against cash settlement for a former Management Board member and non-recurring expenses for discontinued M&A transactions.

Additional Information

FINANCIAL CALENDAR

25 March 2021 - Annual Report 2020
06 May 2021 - Interim Report Q1 2021
19 May 2021 - Annual General Meeting 2021
05 August 2021 - Interim Report Q2 2021
15 September 2021 - Capital Markets Day
04 November 2021 - Interim Report Q3 2021

CONTACT INFORMATION

CompuGroup Medical SE & Co. KGaA
Investor Relations
Maria Trost 21
56070 Koblenz

Telephone: +49 (0) 261 8000-7030
Fax: +49 (0) 261 8000-3200

E-Mail: investor@cgm.com
www.cgm.com

Management Responsibility Statement

To the best of our knowledge, and in accordance with applicable accounting principles for interim financial reporting, the consolidated interim financial statements give a true and fair view of the net assets, financial position and results of operations of the Group, and the Group interim management report includes a fair review of the development and performance of the business and the position of the Group, together with a description of the principal opportunities and risks associated with the expected development of the Group over the remainder of the financial year.

Koblenz, 4 February 2021

CompuGroup Medical SE & Co. KGaA

Represented by the Managing Directors of
CompuGroup Medical Management SE



Dr. Dirk Wössner



Frank Brecher



Dr. Ralph Körfgen



Dr. Eckart Pech



Michael Rauch



Hannes Reichl

CompuGroup Medical SE & Co. KGaA
Maria Trost 21
56070 Koblenz
Germany

Synchronizing Healthcare

